Australien - engelska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Malta - engelska - Medicines Authority

jv healthcare limited - fluorouracil - solution for injection/infusion - fluorouracil 50 milligram(s)/millilitre - antineoplastic agents

Kanada - engelska - Health Canada

accord healthcare inc - fluorouracil - solution - 50mg - fluorouracil 50mg - antineoplastic agents

USA - engelska - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil cream, 0.5% is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp. fluorouracil may cause fetal harm when administered to a pregnant woman. fluorouracil is contraindicated in women who are or may become pregnant. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. no adequate and well-controlled studies have been conducted in pregnant women with either topical or parenteral forms of fluorouracil. one birth defect (ventricular septal defect) and cases of miscarriage have been reported when fluorouracil was applied to mucous membrane areas. multiple birth defects have been reported in the fetus of a patient treated with intravenous fluorouracil. animal reproduction studies have not been conducted with fluorouracil cream, 0.5%. fluorouracil, the active ingredient, has been shown to be teratogenic in mice, rats, and hamsters when adm

USA - engelska - NLM (National Library of Medicine)

xiromed llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil is indicated for the treatment of patients with: 1.1 adenocarcinoma of the colon and rectum 1.2 adenocarcinoma of the breast 1.3 gastric adenocarcinoma 1.4 pancreatic adenocarcinoma none. pregnancy category d risk summary there are no adequate and well-controlled studies with fluorouracil in pregnant women. based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman. administration of fluorouracil to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. malformations included cleft palate and skeletal defects. in monkeys, maternal doses of fluorouracil higher than an approximate human dose of 12 mg/kg resulted in abortion. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus [see clinical pharmacology (12.1)]. animal data malformations including cleft pa

USA - engelska - NLM (National Library of Medicine)

bluepoint laboratories - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil is indicated for the treatment of patients with: 1.1 adenocarcinoma of the colon and rectum 1.2 adenocarcinoma of the breast 1.3 gastric adenocarcinoma 1.4 pancreatic adenocarcinoma none. pregnancy category d risk summary there are no adequate and well-controlled studies with fluorouracil in pregnant women. based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman. administration of fluorouracil to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. malformations included cleft palate and skeletal defects. in monkeys, maternal doses of fluorouracil higher than an approximate human dose of 12 mg/kg resulted in abortion. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus [see clinical pharmacology (12.1)]. animal data